Does rofecoxib , a COX-2 inhibitor , inhibit human gastric mucosal prostaglandin production?
Rofecoxib (50 mg) lacked naproxen's ability to reduce the availability of gastroprotective prostaglandins.
The hENT1 gene specific downregulation by RNAi enhanced 5-FU chemosensitivity in pancreatic cancer cell line Panc-1.